BioCryst Pharmaceuticals, Inc. (FRA:BO1)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.93B +41.8% |
| Revenue (ttm) | 823.32M +68.7% |
| Net Income | -336.70M |
| EPS | -1.47 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 14.77 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 7.50 |
| Previous Close | 7.30 |
| Day's Range | 7.48 - 7.50 |
| 52-Week Range | 5.18 - 10.19 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein i... [Read more]
News
BioCryst Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A shift to external innovation and strategic acquisitions is driving pipeline expansion and profitability, with ORLADEYO and navenibart positioned for complementary growth. The company targets rare diseases with strong science and maintains a strict focus on sustained profitability.
BioCryst to Present at Upcoming Investor Conference
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Globa...
BioCryst is profitable. Now it wants to buy more rare disease drugs
BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize b...
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
BioCryst Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw 45% revenue growth year-over-year, strong ORLADEYO demand, and a successful pediatric launch. Cost discipline and external innovation strategy improved profitability and cash position, with raised revenue guidance for 2026.
BioCryst Pharmaceuticals Earnings release: Q2 2026
BioCryst Pharmaceuticals released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
BioCryst Pharmaceuticals Slides: Q2 2026
BioCryst Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
BioCryst Pharmaceuticals Quarterly report: Q2 2026
BioCryst Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 5, 2026.
BioCryst Reports Second Quarter 2026 Financial Results
— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 O...
BioCryst to Report Second Quarter 2026 Financial Results on August 5
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on ...
BioCryst Appoints David W. Jenkins as Chief Scientific Officer
RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted n...
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and close its Alabama research facility by the end of 2026, as it pivots to external partnerships to b...
BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations
BioCryst Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company is maintaining strong revenue growth for ORLADEYO, with robust new patient demand and a stable payer mix. Navenibart's phase III enrollment will complete soon, with a BLA filing planned for late 2027, and the Netherton syndrome program expects key data by year-end.
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedem...
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 Internati...
BioCryst Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Management outlined a strategy to build a diversified rare disease portfolio by 2030, leveraging ORLADEYO's growth and recent business development moves. Navenibart's pivotal data and BLA filing are expected by end of next year, while the Netherton syndrome program aims for proof-of-concept results by year-end.
BioCryst Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 17% revenue growth and a 25% rise in non-GAAP operating profit, driven by strong ORLADEYO performance and successful Astria integration. Guidance for 2026 is unchanged, with robust liquidity and continued pipeline progress, despite a minor pediatric manufacturing delay.
BioCryst Pharmaceuticals Earnings release: Q1 2026
BioCryst Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
BioCryst Pharmaceuticals Slides: Q1 2026
BioCryst Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
BioCryst Pharmaceuticals Quarterly report: Q1 2026
BioCryst Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —
BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —